Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects

John Q. Trojanowski, Hugo Vandeerstichele, Magdalena Korecka, Christopher M. Clark, Paul S. Aisen, Ronald Carl Petersen, Kaj Blennow, Holly Soares, Adam Simon, Piotr Lewczuk, Robert Dean, Eric Siemers, William Z. Potter, Michael W. Weiner, Clifford R Jr. Jack, William Jagust, Arthur W. Toga, Virginia M Y Lee, Leslie M. Shaw

Research output: Contribution to journalArticle

196 Citations (Scopus)

Abstract

Here, we review progress by the Penn Biomarker Core in the Alzheimer's Disease Neuroimaging Initiative (ADNI) toward developing a pathological cerebrospinal fluid (CSF) and plasma biomarker signature for mild Alzheimer's disease (AD) as well as a biomarker profile that predicts conversion of mild cognitive impairment (MCI) and/or normal control subjects to AD. The Penn Biomarker Core also collaborated with other ADNI Cores to integrate data across ADNI to temporally order changes in clinical measures, imaging data, and chemical biomarkers that serve as mileposts and predictors of the conversion of normal control to MCI as well as MCI to AD, and the progression of AD. Initial CSF studies by the ADNI Biomarker Core revealed a pathological CSF biomarker signature of AD defined by the combination of Aβ1-42 and total tau (T-tau) that effectively delineates mild AD in the large multisite prospective clinical investigation conducted in ADNI. This signature appears to predict conversion from MCI to AD. Data fusion efforts across ADNI Cores generated a model for the temporal ordering of AD biomarkers which suggests that Aβ amyloid biomarkers become abnormal first, followed by changes in neurodegenerative biomarkers (CSF tau, F-18 fluorodeoxyglucose-positron emission tomography, magnetic resonance imaging) with the onset of clinical symptoms. The timing of these changes varies in individual patients due to genetic and environmental factors that increase or decrease an individual's resilience in response to progressive accumulations of AD pathologies. Further studies in ADNI will refine this model and render the biomarkers studied in ADNI more applicable to routine diagnosis and to clinical trials of disease modifying therapies.

Original languageEnglish (US)
Pages (from-to)230-238
Number of pages9
JournalAlzheimer's and Dementia
Volume6
Issue number3
DOIs
StatePublished - May 2010

Fingerprint

Neuroimaging
Alzheimer Disease
Biomarkers
Cerebrospinal Fluid
Fluorodeoxyglucose F18
Amyloid
Positron-Emission Tomography
Disease Progression

Keywords

  • Alzheimer's disease
  • Biomarkers
  • Cerebrospinal fluid
  • Mild cognitive impairment
  • Plasma

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology
  • Medicine(all)

Cite this

Trojanowski, J. Q., Vandeerstichele, H., Korecka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., ... Shaw, L. M. (2010). Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimer's and Dementia, 6(3), 230-238. https://doi.org/10.1016/j.jalz.2010.03.008

Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. / Trojanowski, John Q.; Vandeerstichele, Hugo; Korecka, Magdalena; Clark, Christopher M.; Aisen, Paul S.; Petersen, Ronald Carl; Blennow, Kaj; Soares, Holly; Simon, Adam; Lewczuk, Piotr; Dean, Robert; Siemers, Eric; Potter, William Z.; Weiner, Michael W.; Jack, Clifford R Jr.; Jagust, William; Toga, Arthur W.; Lee, Virginia M Y; Shaw, Leslie M.

In: Alzheimer's and Dementia, Vol. 6, No. 3, 05.2010, p. 230-238.

Research output: Contribution to journalArticle

Trojanowski, JQ, Vandeerstichele, H, Korecka, M, Clark, CM, Aisen, PS, Petersen, RC, Blennow, K, Soares, H, Simon, A, Lewczuk, P, Dean, R, Siemers, E, Potter, WZ, Weiner, MW, Jack, CRJ, Jagust, W, Toga, AW, Lee, VMY & Shaw, LM 2010, 'Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects', Alzheimer's and Dementia, vol. 6, no. 3, pp. 230-238. https://doi.org/10.1016/j.jalz.2010.03.008
Trojanowski, John Q. ; Vandeerstichele, Hugo ; Korecka, Magdalena ; Clark, Christopher M. ; Aisen, Paul S. ; Petersen, Ronald Carl ; Blennow, Kaj ; Soares, Holly ; Simon, Adam ; Lewczuk, Piotr ; Dean, Robert ; Siemers, Eric ; Potter, William Z. ; Weiner, Michael W. ; Jack, Clifford R Jr. ; Jagust, William ; Toga, Arthur W. ; Lee, Virginia M Y ; Shaw, Leslie M. / Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. In: Alzheimer's and Dementia. 2010 ; Vol. 6, No. 3. pp. 230-238.
@article{7b24c2b0b6324e949b6e1da2bc5d8871,
title = "Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects",
abstract = "Here, we review progress by the Penn Biomarker Core in the Alzheimer's Disease Neuroimaging Initiative (ADNI) toward developing a pathological cerebrospinal fluid (CSF) and plasma biomarker signature for mild Alzheimer's disease (AD) as well as a biomarker profile that predicts conversion of mild cognitive impairment (MCI) and/or normal control subjects to AD. The Penn Biomarker Core also collaborated with other ADNI Cores to integrate data across ADNI to temporally order changes in clinical measures, imaging data, and chemical biomarkers that serve as mileposts and predictors of the conversion of normal control to MCI as well as MCI to AD, and the progression of AD. Initial CSF studies by the ADNI Biomarker Core revealed a pathological CSF biomarker signature of AD defined by the combination of Aβ1-42 and total tau (T-tau) that effectively delineates mild AD in the large multisite prospective clinical investigation conducted in ADNI. This signature appears to predict conversion from MCI to AD. Data fusion efforts across ADNI Cores generated a model for the temporal ordering of AD biomarkers which suggests that Aβ amyloid biomarkers become abnormal first, followed by changes in neurodegenerative biomarkers (CSF tau, F-18 fluorodeoxyglucose-positron emission tomography, magnetic resonance imaging) with the onset of clinical symptoms. The timing of these changes varies in individual patients due to genetic and environmental factors that increase or decrease an individual's resilience in response to progressive accumulations of AD pathologies. Further studies in ADNI will refine this model and render the biomarkers studied in ADNI more applicable to routine diagnosis and to clinical trials of disease modifying therapies.",
keywords = "Alzheimer's disease, Biomarkers, Cerebrospinal fluid, Mild cognitive impairment, Plasma",
author = "Trojanowski, {John Q.} and Hugo Vandeerstichele and Magdalena Korecka and Clark, {Christopher M.} and Aisen, {Paul S.} and Petersen, {Ronald Carl} and Kaj Blennow and Holly Soares and Adam Simon and Piotr Lewczuk and Robert Dean and Eric Siemers and Potter, {William Z.} and Weiner, {Michael W.} and Jack, {Clifford R Jr.} and William Jagust and Toga, {Arthur W.} and Lee, {Virginia M Y} and Shaw, {Leslie M.}",
year = "2010",
month = "5",
doi = "10.1016/j.jalz.2010.03.008",
language = "English (US)",
volume = "6",
pages = "230--238",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects

AU - Trojanowski, John Q.

AU - Vandeerstichele, Hugo

AU - Korecka, Magdalena

AU - Clark, Christopher M.

AU - Aisen, Paul S.

AU - Petersen, Ronald Carl

AU - Blennow, Kaj

AU - Soares, Holly

AU - Simon, Adam

AU - Lewczuk, Piotr

AU - Dean, Robert

AU - Siemers, Eric

AU - Potter, William Z.

AU - Weiner, Michael W.

AU - Jack, Clifford R Jr.

AU - Jagust, William

AU - Toga, Arthur W.

AU - Lee, Virginia M Y

AU - Shaw, Leslie M.

PY - 2010/5

Y1 - 2010/5

N2 - Here, we review progress by the Penn Biomarker Core in the Alzheimer's Disease Neuroimaging Initiative (ADNI) toward developing a pathological cerebrospinal fluid (CSF) and plasma biomarker signature for mild Alzheimer's disease (AD) as well as a biomarker profile that predicts conversion of mild cognitive impairment (MCI) and/or normal control subjects to AD. The Penn Biomarker Core also collaborated with other ADNI Cores to integrate data across ADNI to temporally order changes in clinical measures, imaging data, and chemical biomarkers that serve as mileposts and predictors of the conversion of normal control to MCI as well as MCI to AD, and the progression of AD. Initial CSF studies by the ADNI Biomarker Core revealed a pathological CSF biomarker signature of AD defined by the combination of Aβ1-42 and total tau (T-tau) that effectively delineates mild AD in the large multisite prospective clinical investigation conducted in ADNI. This signature appears to predict conversion from MCI to AD. Data fusion efforts across ADNI Cores generated a model for the temporal ordering of AD biomarkers which suggests that Aβ amyloid biomarkers become abnormal first, followed by changes in neurodegenerative biomarkers (CSF tau, F-18 fluorodeoxyglucose-positron emission tomography, magnetic resonance imaging) with the onset of clinical symptoms. The timing of these changes varies in individual patients due to genetic and environmental factors that increase or decrease an individual's resilience in response to progressive accumulations of AD pathologies. Further studies in ADNI will refine this model and render the biomarkers studied in ADNI more applicable to routine diagnosis and to clinical trials of disease modifying therapies.

AB - Here, we review progress by the Penn Biomarker Core in the Alzheimer's Disease Neuroimaging Initiative (ADNI) toward developing a pathological cerebrospinal fluid (CSF) and plasma biomarker signature for mild Alzheimer's disease (AD) as well as a biomarker profile that predicts conversion of mild cognitive impairment (MCI) and/or normal control subjects to AD. The Penn Biomarker Core also collaborated with other ADNI Cores to integrate data across ADNI to temporally order changes in clinical measures, imaging data, and chemical biomarkers that serve as mileposts and predictors of the conversion of normal control to MCI as well as MCI to AD, and the progression of AD. Initial CSF studies by the ADNI Biomarker Core revealed a pathological CSF biomarker signature of AD defined by the combination of Aβ1-42 and total tau (T-tau) that effectively delineates mild AD in the large multisite prospective clinical investigation conducted in ADNI. This signature appears to predict conversion from MCI to AD. Data fusion efforts across ADNI Cores generated a model for the temporal ordering of AD biomarkers which suggests that Aβ amyloid biomarkers become abnormal first, followed by changes in neurodegenerative biomarkers (CSF tau, F-18 fluorodeoxyglucose-positron emission tomography, magnetic resonance imaging) with the onset of clinical symptoms. The timing of these changes varies in individual patients due to genetic and environmental factors that increase or decrease an individual's resilience in response to progressive accumulations of AD pathologies. Further studies in ADNI will refine this model and render the biomarkers studied in ADNI more applicable to routine diagnosis and to clinical trials of disease modifying therapies.

KW - Alzheimer's disease

KW - Biomarkers

KW - Cerebrospinal fluid

KW - Mild cognitive impairment

KW - Plasma

UR - http://www.scopus.com/inward/record.url?scp=77955483685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955483685&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2010.03.008

DO - 10.1016/j.jalz.2010.03.008

M3 - Article

C2 - 20451871

AN - SCOPUS:77955483685

VL - 6

SP - 230

EP - 238

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 3

ER -